METHOD OF PREDICTING EFFECT OF INFLIXIMAB THERAPY IN CHILDREN WITH CROHN'S DISEASE Russian patent published in 2014 - IPC G01N33/52 

FIELD: chemistry.

SUBSTANCE: carried out are: determination of the serum concentration of a factor of a tumour necrosis alpha (TNF-α), evaluation of a relative content of Th17-lymphocytes (%CD3+CD4+CD161+ ot CD3+CD4+) and an activity of succinatedehydrogenase in a population of regulatory T-cells (CD3+CD4+CD127low) (SDH-Treg) before and on the following day after infliximab introduction. A prognostic factor of the medicine efficiency K is calculated by formula. If the factor value is K<0.5, a minimal therapeutic effect of infliximab is predicted. When K=0.5-1.5, a moderate therapeutic effect, which demands correction of the medicine introduction plan, is predicted. If K is from over 1.5 to 2.5, a positive effect from introduction of infliximab is predicted.

EFFECT: possibility to predict long-term, not less than 1 year, effect from the infliximab therapy at any stage of therapy.

4 dwg, 2 tbl, 3 ex